Ceruvia Lifesciences

Ceruvia Lifesciences is a private, clinical-stage biotech company pioneering an entirely new approach to psychiatric and neurological disorders by leveraging psychedelic drug development. The company's mission is to transform psychedelic research into cutting-edge medicine, focusing on non-hallucinogenic analogs to improve patient access and safety. With decades of experience in clinical drug development and commercialization, Ceruvia is advancing its lead candidate, BOL-148, through clinical research to establish safety and efficacy. The company is positioned at the forefront of the emerging neurotransformational medicine field, aiming to deliver meaningful relief to underserved patient communities.

Platform focused on developing non-hallucinogenic analogs of classic psychedelic compounds (e.g., LSD) to retain therapeutic neurological effects while improving safety and clinical practicality.

Total raised: $10M

Ceruvia competes in the psychedelic medicine sector with companies like COMPASS Pathways, MindMed, Atai Life Sciences, and GH Research. Its primary differentiation is the development of non-hallucinogenic LSD analogs (BOL-148), aiming to overcome the practical and safety limitations of hallucinogenic therapies, and its strong academic collaborations with Yale, NYU, and Harvard.